It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The IRE1α/XBP1 branch of unfolded protein response (UPR) pathway has a critical function in endoplasmic reticulum (ER) expansion in plasma cells via unknown mechanisms; interestingly, another UPR branch, PERK, is suppressed during plasma cell development. Here we show that Ufbp1, a target and cofactor of the ufmylation pathway, promotes plasma cell development by suppressing the activation of PERK. By contrast, the IRE1α/XBP1 axis upregulates the expression of Ufbp1 and ufmylation pathway genes in plasma cells, while Ufbp1 deficiency impairs ER expansion in plasma cells and retards immunoglobulin production. Structure and function analysis suggests that lysine 267 of Ufbp1, the main lysine in Ufbp1 that undergoes ufmylation, is dispensable for the development of plasmablasts, but is required for immunoglobulin production and stimulation of ER expansion in IRE1α-deficient plasmablasts. Thus, Ufbp1 distinctly regulates different branches of UPR pathway to promote plasma cell development and function.
IRE1 and PERK, both important mediators of the unfold protein response pathway, are differentially regulated during plasma cell differentiation. Here the authors show that an ufmylation target, Ufbp1, suppresses PERK to stimulate plasma cell development and is induced by the IRE1/XBP1 pathway to promote ER expansion .
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Savage, Natasha M 5 ; Sharma, Ashok 4 ; Kaufman, Randal J 6
; Li, Honglin 7 ; Singh, Nagendra 7
1 Augusta University, Department of Biochemistry and Molecular Biology, Augusta, USA (GRID:grid.410427.4) (ISNI:0000 0001 2284 9329)
2 Augusta University, Department of Biochemistry and Molecular Biology, Augusta, USA (GRID:grid.410427.4) (ISNI:0000 0001 2284 9329); Texas Tech University Health Sciences Center, Department of Cell Biology and Biochemistry, Lubbock, USA (GRID:grid.416992.1) (ISNI:0000 0001 2179 3554)
3 Nanjing Agricultural University, College of Animal Science and Technology, Nanjing, China (GRID:grid.27871.3b) (ISNI:0000 0000 9750 7019)
4 Augusta University, Center for Biotechnology and Genomic Medicine, Augusta, USA (GRID:grid.410427.4) (ISNI:0000 0001 2284 9329)
5 Augusta University, Department of Pathology, Augusta, USA (GRID:grid.410427.4) (ISNI:0000 0001 2284 9329)
6 Sanford Burnham Prebys Medical Discovery Institute, Degenerative Diseases Program, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573)
7 Augusta University, Department of Biochemistry and Molecular Biology, Augusta, USA (GRID:grid.410427.4) (ISNI:0000 0001 2284 9329); Augusta University, Georgia Cancer Center, Augusta, USA (GRID:grid.410427.4) (ISNI:0000 0001 2284 9329)




